Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes

Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a select...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Melissa A., Song, Yuanbin, Arrate, Maria P., Gbyli, Rana, Villaume, Matthew T., Smith, Brianna N., Childress, Merrida A., Stricker, Thomas P., Halene, Stephanie, Savona, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Myelodysplastic Syndromes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890032/
https://www.ncbi.nlm.nih.gov/pubmed/35979721
http://dx.doi.org/10.3324/haematol.2022.280631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890032/
https://www.ncbi.nlm.nih.gov/pubmed/35979721
http://dx.doi.org/10.3324/haematol.2022.280631

Ejemplares similares